Pathology of demyelinating diseases

Annual Review of Pathology: Mechanisms of Disease

Volumn 7, Issue , 2012, Pages 185-217

  Popescu, Bogdan F Gh ^a,b   Lucchinetti, Claudia F ^b  

^a UNIVERSITY OF SASKATCHEWAN   (Canada)

^b MAYO CLINIC   (United States)

Author keywords

Acute disseminated encephalomyelitis; Acute hemorrhagic leukoencephalitis; Balo's concentric sclerosis; Marburg disease; Multiple sclerosis; Neuromyelitis optica

Indexed keywords

2',3' CYCLIC NUCLEOTIDE 3' PHOSPHODIESTERASE; AMYLOID BETA PROTEIN; AQUAPORIN 4; CHEMOKINE RECEPTOR CCR1; CHEMOKINE RECEPTOR CCR5; GLIAL FIBRILLARY ACIDIC PROTEIN; HEME OXYGENASE 1; HYPOXIA INDUCIBLE FACTOR 1ALPHA; IMMUNOGLOBULIN; IMMUNOGLOBULIN G ANTIBODY; INDUCIBLE NITRIC OXIDE SYNTHASE; INTERLEUKIN 10; INTERLEUKIN 4; IRON; LACTOSYLCERAMIDE; MYELIN ASSOCIATED GLYCOPROTEIN; MYELIN OLIGODENDROCYTE GLYCOPROTEIN; MYELOPEROXIDASE;

ACUTE DISSEMINATED ENCEPHALOMYELITIS; APOPTOSIS; ASTROCYTOSIS; B LYMPHOCYTE; BLOOD BRAIN BARRIER; BRAIN CORTEX; BRAIN STEM; CEREBELLUM; COMPLEMENT ACTIVATION; COMPLEMENT DEPOSITION; CYTOKINE RELEASE; DEMYELINATING DISEASE; DEMYELINATION; DISEASE CLASSIFICATION; DISEASE COURSE; DOWN REGULATION; ENDOCYTOSIS; GLIOSIS; HUMAN; IMMUNOHISTOCHEMISTRY; INCIDENCE; INFLAMMATION; LYMPHOCYTIC INFILTRATION; MACROPHAGE; MENINGITIS; MULTIPLE SCLEROSIS; MYELOOPTIC NEUROPATHY; NEUROIMAGING; OLIGODENDROGLIA; OPTIC NERVE; PELIZAEUS MERZBACHER DISEASE; PREVALENCE; PRIORITY JOURNAL; REMYELINIZATION; REVIEW; SPINAL CORD; T LYMPHOCYTE; UPREGULATION; WALKING AID; WHITE MATTER;

DEMYELINATING DISEASES; DIFFUSE CEREBRAL SCLEROSIS OF SCHILDER; ENCEPHALOMYELITIS, ACUTE DISSEMINATED; HUMANS; INFLAMMATION; MULTIPLE SCLEROSIS; NEUROMYELITIS OPTICA;

EID: 84856884830     PISSN: 15534006     EISSN: 15534014     Source Type: Book Series    
DOI: 10.1146/annurev-pathol-011811-132443     Document Type: Review

References (150)

1. Sobel RA, Moore GRW. 2008. Demyelinating diseases. In Greenfield's Neuropathology, ed. S Love, DN Louis, DW Ellison, pp. 1513-608. New York: Oxford Univ. Press
2. Kuhlmann T, Lassmann H, BruckW. 2008. Diagnosis of inflammatory demyelination in biopsy specimens: a practical approach. Acta Neuropathol. 115:275-87
3. Anderson DW, Ellenberg JH, Leventhal CM, Reingold SC, Rodriguez M, Silberberg DH. 1992. Revised estimate of the prevalence of multiple sclerosis in the United States. Ann. Neurol. 31:333-36
4. Weinshenker BG, Bass B, Rice GP, Noseworthy J, Carriere W, et al. 1989. The natural history of multiple sclerosis: a geographically based study. I. Clinical course and disability. Brain 112(Part 1):133-46 (Pubitemid 19056478)
5. Ascherio A, Munger KL. 2010. Epidemioloy of multiple sclerosis: environmental factors. In Multiple Sclerosis 3, ed. CF Lucchinetti, R Hohlfeld, pp. 57-82. Philadelphia: Saunders Elsevier
6. Prineas JW, Kwon EE, Cho ES, Sharer LR, Barnett MH, et al. 2001. Immunopathology of secondaryprogressive multiple sclerosis. Ann. Neurol. 50:646-57
7. Love S. 2006. Demyelinating diseases. J. Clin. Pathol. 59:1151-59 (Pubitemid 44787134)
8. BruckW, Porada P, Poser S, Rieckmann P, Hanefeld F, et al. 1995. Monocyte/macrophage differentiation in early multiple sclerosis lesions. Ann. Neurol. 38:788-96
9. Lucchinetti C, Bruck W. 2004. The pathology of primary progressive multiple sclerosis. Mult. Scler. 10(Suppl. 1):23-30
10. Rotshenker S. 2003. Microglia and macrophage activation and the regulation of complement-receptor 3 (CR3/MAC-1)-mediated myelin phagocytosis in injury and disease. J. Mol. Neurosci. 21:65-72 (Pubitemid 37204874)
11. Prineas JW, Graham JS. 1981. Multiple sclerosis: capping of surface immunoglobulinGonmacrophages engaged in myelin breakdown. Ann. Neurol. 10:149-58 (Pubitemid 11053101)
12. Lucchinetti C, Bruck W, Parisi J, Scheithauer B, Rodriguez M, Lassmann H. 2000. Heterogeneity of multiple sclerosis lesions: implications for the pathogenesis of demyelination. Ann. Neurol. 47:707-17 (Pubitemid 30390191)
13. Probert L, Akassoglou K, Pasparakis M, Kontogeorgos G, Kollias G. 1995. Spontaneous inflammatory demyelinating disease in transgenic mice showing central nervous system-specific expression of tumor necrosis factor alpha. Proc. Natl. Acad. Sci. USA 92:11294-98
14. Griot C, Vandevelde M, Richard A, Peterhans E, Stocker R. 1990. Selective degeneration of oligodendrocytes mediated by reactive oxygen species. Free Radic. Res. Commun. 11:181-93
15. Storch MK, Stefferl A, Brehm U, Weissert R, Wallstrom E, et al. 1998. Autoimmunity to myelin oligodendrocyte glycoprotein in rats mimics the spectrum of multiple sclerosis pathology. Brain Pathol. 8:681-94 (Pubitemid 28460927)
16. Burgoon MP, Gilden DH, Owens GP. 2004. B cells in multiple sclerosis. Front. Biosci. 9:786-96 (Pubitemid 39043751)
17. Raine CS, Johnson AB, Marcus DM, Suzuki A, Bornstein MB. 1981. Demyelination in vitro. Absorption studies demonstrate that galactocerebroside is a major target. J. Neurol. Sci. 52:117-31 (Pubitemid 11018934)
18. O'Connor KC, McLaughlin KA, De Jager PL, Chitnis T, Bettelli E, et al. 2007. Self-antigen tetramers discriminate between myelin autoantibodies to native or denatured protein. Nat. Med. 13:211-17
19. Lennon VA, Wingerchuk DM, Kryzer TJ, Pittock SJ, Lucchinetti CF, et al. 2004. A serum autoantibody marker of neuromyelitis optica: distinction from multiple sclerosis. Lancet 364:2106-12 (Pubitemid 39626806)
20. Lennon VA, Kryzer TJ, Pittock SJ, Verkman AS, Hinson SR. 2005. IgG marker of optic-spinal multiple sclerosis binds to the aquaporin-4 water channel. J. Exp. Med. 202:473-77 (Pubitemid 41186945)
21. Chiba S, Yokota S, Yonekura K, Tanaka S, Furuyama H, et al. 2006. Autoantibodies against HSP70 family proteins were detected in the cerebrospinal fluid from patients with multiple sclerosis. J. Neurol. Sci. 241:39-43 (Pubitemid 43112514)
22. Zhang Y, Da RR, Hilgenberg LG, Tourtellotte WW, Sobel RA, et al. 2005. Clonal expansion of IgA-positive plasma cells and axon-reactive antibodies in MS lesions. J. Neuroimmunol. 167:120-30 (Pubitemid 41244805)
23. RodriguezM. 1985. Virus-induced demyelination in mice: "dying back" of oligodendrocytes. Mayo Clin. Proc. 60:433-38 (Pubitemid 15249990)
24. Ludwin SK, Johnson ES. 1981. Evidence for a "dying-back" gliopathy in demyelinating disease. Ann. Neurol. 9:301-5 (Pubitemid 11147150)
25. Aboul-Enein F, Rauschka H, Kornek B, Stadelmann C, Stefferl A, et al. 2003. Preferential loss of myelin-associated glycoprotein reflects hypoxia-like white matter damage in stroke and inflammatory brain diseases. J. Neuropathol. Exp. Neurol. 62:25-33 (Pubitemid 36068890)
26. Lassmann H. 2003. Hypoxia-like tissue injury as a component of multiple sclerosis lesions. J. Neurol. Sci. 206:187-91 (Pubitemid 36143726)
27. Aboul-Enein F, Lassmann H. 2005. Mitochondrial damage and histotoxic hypoxia: a pathway of tissue injury in inflammatory brain disease? Acta Neuropathol 109:49-55 (Pubitemid 40287789)
28. Mahad D, Ziabreva I, Lassmann H, Turnbull D. 2008. Mitochondrial defects in acute multiple sclerosis lesions. Brain 131:1722-35 (Pubitemid 351957459)
29. Jurewicz A, Matysiak M, Tybor K, Kilianek L, Raine CS, Selmaj K. 2005. Tumour necrosis factor- induced death of adult human oligodendrocytes ismediated by apoptosis inducing factor. Brain 128:2675-88 (Pubitemid 41552951)
30. Lu F, Selak M, O'Connor J, Croul S, Lorenzana C, et al. 2000. Oxidative damage to mitochondrial DNA and activity of mitochondrial enzymes in chronic active lesions of multiple sclerosis. J. Neurol. Sci. 177:95-103
31. Mehindate K, Sahlas DJ, Frankel D, Mawal Y, Liberman A, et al. 2001. Proinflammatory cytokines promote glial heme oxygenase 1 expression and mitochondrial iron deposition: implications for multiple sclerosis. J. Neurochem. 77:1386-95 (Pubitemid 32523691)
32. Barnett MH, Prineas JW. 2004. Relapsing and remitting multiple sclerosis: pathology of the newly forming lesion. Ann. Neurol. 55:458-68 (Pubitemid 38391962)
33. Mahad DJ, Trebst C, Kivisakk P, Staugaitis SM, Tucky B, et al. 2004. Expression of chemokine receptors CCR1 and CCR5 reflects differential activation of mononuclear phagocytes in pattern II and pattern III multiple sclerosis lesions. J. Neuropathol. Exp. Neurol. 63:262-73 (Pubitemid 38327946)
34. Quintana FJ, Mimran A, Carmi P, Mor F, Cohen IR. 2008. HSP60 as a target of anti-ergotypic regulatory T cells. PLoS ONE 3:e4026
35. Marik C, Felts PA, Bauer J, Lassmann H, Smith KJ. 2007. Lesion genesis in a subset of patients with multiple sclerosis: a role for innate immunity? Brain 130:2800-15 (Pubitemid 350033973)
36. Lucchinetti CF, Altintas A, Wegner C, Menk S, Lassmann H, et al. 2003. Magnetic resonance imaging correlates of multiple sclerosis pathologic subtypes. Ann. Neurol. 54(Suppl. 7):67
37. Keegan M, Konig F, McClelland R, Bruck W, Morales Y, et al. 2005. Relation between humoral pathological changes in multiple sclerosis and response to therapeutic plasma exchange. Lancet 366:579-82 (Pubitemid 41140333)
38. Lassmann H, Bruck W, Lucchinetti C, Rodriguez M. 1997. Remyelination in multiple sclerosis. Mult. Scler. 3:133-36 (Pubitemid 27390387)
39. Foote AK, BlakemoreWF. 2005. Inflammation stimulates remyelination in areas of chronic demyelination. Brain 128:528-39 (Pubitemid 40380188)
40. Glezer I, Lapointe A, Rivest S. 2006. Innate immunity triggers oligodendrocyte progenitor reactivity and confines damages to brain injuries. FASEB J. 20:750-52 (Pubitemid 46671203)
41. Bitsch A, Kuhlmann T, Da Costa C, Bunkowski S, Polak T, Bruck W. 2000. Tumour necrosis factor mRNA expression in early multiple sclerosis lesions: correlation with demyelinating activity and oligodendrocyte pathology. Glia 29:366-75 (Pubitemid 30121426)
42. Bar-Or A. 2005. Immunology of multiple sclerosis. Neurol. Clin. 23:149-75 (Pubitemid 40126919)
43. Pitt D, Werner P, Raine CS. 2000. Glutamate excitotoxicity in a model of multiple sclerosis. Nat. Med. 6:67-70 (Pubitemid 30048528)
44. Selmaj K, Cross AH, Farooq M, Brosnan CF, RaineCS. 1991. Non-specific oligodendrocyte cytotoxicity mediated by soluble products of activated T cell lines. J. Neuroimmunol. 35:261-71
45. D'Souza SD, Bonetti B, Balasingam V, Cashman NR, Barker PA, et al. 1996. Multiple sclerosis: Fas signaling in oligodendrocyte cell death. J. Exp. Med. 184:2361-70 (Pubitemid 27023735)
46. Jurewicz A, Biddison WE, Antel JP. 1998. MHC class I-restricted lysis of human oligodendrocytes by myelin basic protein peptide-specific CD8 T lymphocytes. J. Immunol. 160:3056-59 (Pubitemid 28136763)
47. Merrill JE, Scolding NJ. 1999. Mechanisms of damage to myelin and oligodendrocytes and their relevance to disease. Neuropathol. Appl. Neurobiol. 25:435-58 (Pubitemid 30045419)
48. Stadelmann C, Kerschensteiner M, Misgeld T, Bruck W, Hohlfeld R, Lassmann H. 2002. BDNF and gp145trkB inmultiple sclerosis brain lesions: neuroprotective interactions between immune and neuronal cells? Brain 125:75-85 (Pubitemid 34084038)
49. Barkhof F, Bruck W, De Groot CJ, Bergers E, Hulshof S, et al. 2003. Remyelinated lesions in multiple sclerosis: magnetic resonance image appearance. Arch. Neurol. 60:1073-81 (Pubitemid 36975794)
50. Patrikios P, Stadelmann C, Kutzelnigg A, Rauschka H, Schmidbauer M, et al. 2006. Remyelination is extensive in a subset of multiple sclerosis patients. Brain 129:3165-72 (Pubitemid 44871433)
51. Bramow S, Frischer JM, Lassmann H, Koch-Henriksen N, Lucchinetti CF, et al. 2010. Demyelination versus remyelination in progressive multiple sclerosis. Brain 133:2983-98
52. Wolswijk G. 1998. Chronic stage multiple sclerosis lesions contain a relatively quiescent population of oligodendrocyte precursor cells. J. Neurosci. 18:601-9 (Pubitemid 28041896)
53. BlakemoreWF, Chari DM, Gilson JM, Crang AJ. 2002. Modelling large areas of demyelination in the rat reveals the potential and possible limitations of transplanted glial cells for remyelination in the CNS. Glia 38:155-68
54. BlakemoreWF, Franklin RJ. 2008. Remyelination in experimental models of toxin-induced demyelination. Curr. Top. Microbiol. Immunol. 318:193-212
55. Kuhlmann T, Miron V, Cui Q, Wegner C, Antel J, Bruck W. 2008. Differentiation block of oligodendroglial progenitor cells as a cause for remyelination failure in chronic multiple sclerosis. Brain 131:1749-58 (Pubitemid 351957453)
56. Johnson ES, Ludwin SK. 1981. The demonstration of recurrent demyelination and remyelination of axons in the central nervous system. Acta Neuropathol. 53:93-98 (Pubitemid 11167544)
57. Coman I, Barbin G, Charles P, Zalc B, Lubetzki C. 2005. Axonal signals in central nervous system myelination, demyelination and remyelination. J. Neurol. Sci. 233:67-71 (Pubitemid 40804818)
58. Holley JE, Gveric D, Newcombe J, Cuzner ML, Gutowski NJ. 2003. Astrocyte characterization in the multiple sclerosis glial scar. Neuropathol. Appl. Neurobiol. 29:434-44 (Pubitemid 37222717)
59. Prineas JW, Kwon EE, Goldenberg PZ, Cho ES, Sharer LR. 1990. Interaction of astrocytes and newly formed oligodendrocytes in resolving multiple sclerosis lesions. Lab. Investig. 63:624-36
60. Chari DM, Crang AJ, BlakemoreWF. 2003. Decline in rate of colonization of oligodendrocyte progenitor cell (OPC)-depleted tissue by adult OPCs with age. J. Neuropathol. Exp. Neurol. 62:908-16 (Pubitemid 37159031)
61. Sim FJ, Hinks GL, Franklin RJ. 2000. The re-expression of the homeodomain transcription factor Gtx during remyelination of experimentally induced demyelinating lesions in young and old rat brain. Neuroscience 100:131-39 (Pubitemid 30670307)
62. Kornek B, Storch MK, Weissert R, Wallstroem E, Stefferl A, et al. 2000. Multiple sclerosis and chronic autoimmune encephalomyelitis: a comparative quantitative study of axonal injury in active, inactive, and remyelinated lesions. Am. J. Pathol. 157:267-76 (Pubitemid 30641742)
63. Frischer JM, Bramow S, Dal-Bianco A, Lucchinetti CF, Rauschka H, et al. 2009. The relation between inflammation and neurodegeneration in multiple sclerosis brains. Brain 132:1175-89
64. Kutzelnigg A, Lucchinetti CF, Stadelmann C, BruckW, RauschkaH, et al. 2005. Cortical demyelination and diffuse white matter injury in multiple sclerosis. Brain 128:2705-12 (Pubitemid 41552953)
65. DeLuca GC, Ebers GC, Esiri MM. 2004. Axonal loss in multiple sclerosis: a pathological survey of the corticospinal and sensory tracts. Brain 127:1009-18 (Pubitemid 38623038)
66. Huizinga R, Heijmans N, Schubert P, Gschmeissner S, 't Hart BA, et al. 2007. Immunization with neurofilament light protein induces spastic paresis and axonal degeneration in Biozzi ABH mice. J. Neuropathol. Exp. Neurol. 66:295-304 (Pubitemid 46559022)
67. Mor F, Quintana F, Mimran A, Cohen IR. 2003. Autoimmune encephalomyelitis and uveitis induced by T cell immunity to self α-synuclein. J. Immunol. 170:628-34 (Pubitemid 36026192)
68. Mathey EK, Derfuss T, Storch MK, Williams KR, Hales K, et al. 2007. Neurofascin as a novel target for autoantibody-mediated axonal injury. J. Exp. Med. 204:2363-72 (Pubitemid 47529322)
69. Derfuss T, Parikh K, Velhin S, Braun M, Mathey E, et al. 2009. Contactin-2/TAG-1-directed autoimmunity is identified in multiple sclerosis patients and mediates gray matter pathology in animals. Proc. Natl. Acad. Sci. USA 106:8302-7
70. Lassmann H. 2003. Axonal injury in multiple sclerosis. J. Neurol. Neurosurg. Psychiatry 74:695-97 (Pubitemid 36628275)
71. Evangelou N, Konz D, Esiri MM, Smith S, Palace J, Matthews PM. 2000. Regional axonal loss in the corpus callosum correlates with cerebral whitematter lesion volume and distribution inmultiple sclerosis. Brain 123(Part 9):1845-49 (Pubitemid 30664287)
72. DeLucaGC, Williams K, Evangelou N, Ebers GC, Esiri MM. 2006. The contribution of demyelination to axonal loss in multiple sclerosis. Brain 129:1507-16 (Pubitemid 43999383)
73. Evangelou N, DeLuca GC, Owens T, Esiri MM. 2005. Pathological study of spinal cord atrophy in multiple sclerosis suggests limited role of local lesions. Brain 128:29-34 (Pubitemid 40070517)
74. Brownell B, Hughes JT. 1962. The distribution of plaques in the cerebrum in multiple sclerosis. J. Neurol. Neurosurg. Psychiatry 25:315-20
75. Bo L, Vedeler CA, Nyland H, Trapp BD, Mork SJ. 2003. Intracortical multiple sclerosis lesions are not associated with increased lymphocyte infiltration. Mult. Scler. 9:323-31 (Pubitemid 36958014)
76. Bo L, Vedeler CA, Nyland HI, Trapp BD, Mork SJ. 2003. Subpial demyelination in the cerebral cortex of multiple sclerosis patients. J. Neuropathol. Exp. Neurol. 62:723-32 (Pubitemid 36870458)
77. Kidd D, Barkhof F, McConnell R, Algra PR, Allen IV, Revesz T. 1999. Cortical lesions in multiple sclerosis. Brain 122(Part 1):17-26 (Pubitemid 29046269)
78. Peterson JW, Bo L, Mork S, Chang A, Trapp BD. 2001. Transected neurites, apoptotic neurons, and reduced inflammation in cortical multiple sclerosis lesions. Ann. Neurol. 50:389-400 (Pubitemid 32848742)
79. Richert ND, Ostuni JL, Bash CN, Duyn JH, McFarland HF, Frank JA. 1998. Serial whole-brain magnetization transfer imaging in patients with relapsing-remitting multiple sclerosis at baseline and during treatment with interferon β1b. Am. J. Neuroradiol. 19:1705-13 (Pubitemid 30413762)
80. Wegner C, Esiri MM, Chance SA, Palace J, Matthews PM. 2006. Neocortical neuronal, synaptic, and glial loss in multiple sclerosis. Neurology 67:960-67 (Pubitemid 44454585)
81. Lumsden C. 1970. The neuropathology of multiple sclerosis. In Handbook of Clinical Neurology, ed. P Vinken, G Bruyn, pp. 217-309. New York: Elsevier
82. Popescu BF, Bunyan RF, Parisi JE, Ransohoff RM, Lucchinetti C. 2011. A case of multiple sclerosis presenting with inflammatory cortical demyelination. Neurology 76:1705-10
83. Kutzelnigg A, Faber-Rod JC, Bauer J, Lucchinetti CF, Sorensen PS, et al. 2007. Widespread demyelination in the cerebellar cortex in multiple sclerosis. Brain Pathol. 17:38-44
84. Magliozzi R, Howell O, Vora A, Serafini B, Nicholas R, et al. 2007. MeningealB-cell follicles in secondary progressive multiple sclerosis associate with early onset of disease and severe cortical pathology. Brain 130:1089-104 (Pubitemid 47355604)
85. Serafini B, Rosicarelli B, Magliozzi R, Stigliano E, Aloisi F. 2004. Detection of ectopic B-cell follicles with germinal centers in the meninges of patients with secondary progressive multiple sclerosis. Brain Pathol. 14:164-74 (Pubitemid 38656388)
86. Serafini B, Rosicarelli B, Franciotta D, Magliozzi R, Reynolds R, et al. 2007. Dysregulated Epstein-Barr virus infection in the multiple sclerosis brain. J. Exp. Med. 204:2899-912 (Pubitemid 350179559)
87. Vercellino M, Plano F, Votta B, Mutani R, Giordana MT, Cavalla P. 2005. Grey matter pathology in multiple sclerosis. J. Neuropathol. Exp. Neurol. 64:1101-7
88. VrenkenH, Pouwels PJ, Geurts JJ, Knol DL, PolmanCH, et al. 2006. Altered diffusion tensor in multiple sclerosis normal-appearing brain tissue: cortical diffusion changes seem related to clinical deterioration. J. Magn. Reson. Imaging 23:628-36
89. Calabrese M, Gallo P. 2009. Magnetic resonance evidence of cortical onset of multiple sclerosis. Mult. Scler. 15:933-41
90. De Stefano N, Matthews PM, Filippi M, Agosta F, De Luca M, et al. 2003. Evidence of early cortical atrophy in MS: relevance to white matter changes and disability. Neurology 60:1157-62 (Pubitemid 36418778)
91. Amato MP, Bartolozzi ML, Zipoli V, Portaccio E, Mortilla M, et al. 2004. Neocortical volume decrease in relapsing-remitting MS patients with mild cognitive impairment. Neurology 63:89-93 (Pubitemid 38943784)
92. Audoin B, Ranjeva JP, Au DuongMV, Ibarrola D, Malikova I, et al. 2004. Voxel-based analysis ofMTR images: a method to locate graymatter abnormalities in patients at the earliest stage ofmultiple sclerosis. J. Magn. Reson. Imaging 20:765-71 (Pubitemid 39426070)
93. Sharma R, Narayana PA, Wolinsky JS. 2001. Grey matter abnormalities in multiple sclerosis: proton magnetic resonance spectroscopic imaging. Mult. Scler. 7:221-26 (Pubitemid 32780691)
94. Bo L, Geurts JJ, van der Valk P, Polman C, Barkhof F. 2007. Lack of correlation between cortical demyelination and white matter pathologic changes in multiple sclerosis. Arch. Neurol. 64:76-80 (Pubitemid 46072427)
95. Merkler D, Ernsting T, Kerschensteiner M, BruckW, Stadelmann C. 2006. A new focal EAE model of cortical demyelination: multiple sclerosis-like lesions with rapid resolution of inflammation and extensive remyelination. Brain 129:1972-83 (Pubitemid 44289063)
96. Lassmann H, Wisniewski HM. 1978. Chronic relapsing EAE. Time course of neurological symptoms and pathology. Acta Neuropathol. 43:35-42 (Pubitemid 8407036)
97. Brown DA, Sawchenko PE. 2007. Time course and distribution of inflammatory and neurodegenerative events suggest structural bases for the pathogenesis of experimental autoimmune encephalomyelitis. J. Comp. Neurol. 502:236-60 (Pubitemid 46595397)
98. Weller RO, Engelhardt B, Phillips MJ. 1996. Lymphocyte targeting of the central nervous system: a review of afferent and efferent CNS-immune pathways. Brain Pathol. 6:275-88 (Pubitemid 26246383)
99. Mendez MF, Pogacar S. 1988. Malignant monophasic multiple sclerosis or "Marburg's disease". Neurology 38:1153-55
100. Stadelmann C, BruckW. 2004. Lessons from the neuropathology of atypical forms of multiple sclerosis. Neurol. Sci. 25(Suppl. 4):S319-22 (Pubitemid 39600424)
101. Genain CP, Cannella B, Hauser SL, Raine CS. 1999. Identification of autoantibodies associated with myelin damage in multiple sclerosis. Nat. Med. 5:170-75 (Pubitemid 29068523)
102. Tabira T. 1994. Concentric sclerosis (Balo). Nippon Rinsho 52:2971-75
103. Karaarslan E, Altintas A, Senol U, Yeni N, Dincer A, et al. 2001. Balo's concentric sclerosis: clinical and radiologic features of five cases. Am. J. Neuroradiol. 22:1362-67 (Pubitemid 32734812)
104. Moore GR, Berry K, Oger JJ, Prout AJ, Graeb DA, Nugent RA. 2001. Balo's concentric sclerosis: surviving normal myelin in a patient with a relapsing-remitting clinical course. Mult. Scler. 7:375-82 (Pubitemid 33138348)
105. Moore GR, Neumann PE, Suzuki K, Lijtmaer HN, Traugott U, Raine CS. 1985. Balo's concentric sclerosis: new observations on lesion development. Ann. Neurol. 17:604-11 (Pubitemid 15055580)
106. Yao DL, Webster HD, Hudson LD, Brenner M, Liu DS, et al. 1994. Concentric sclerosis (Balo): morphometric and in situ hybridization study of lesions in six patients. Ann. Neurol. 35:18-30
107. Stadelmann C, Ludwin S, Tabira T, Guseo A, Lucchinetti CF, et al. 2005. Tissue preconditioning may explain concentric lesions in Balo's type of multiple sclerosis. Brain 128:979-87 (Pubitemid 40675454)
108. Courville CB. 1970. Concentric sclerosis. In Handbook of Clinical Neurology, ed. PJ Vinken, GW Bruyn, pp. 437-51. Amsterdam: North Holland
109. Hallervorden J, Spatz H. 1933. About concentric sclerosis and the physical-chemical factors governing the propagation phenomena in the white matter. Arch. Psychiat. Nervenkrankh. 98:641-701 (from German)
110. Khonsari RH, Calvez V. 2007. The origins of concentric demyelination: self-organization in the human brain. PLoS ONE 2:e150
111. WingerchukDM.2006. The clinical course of acute disseminated encephalomyelitis. Neurol. Res. 28:341-47 (Pubitemid 43765122)
112. Young NP, Weinshenker BG, Parisi JE, Scheithauer B, Giannini C, et al. 2010. Perivenous demyelination: association with clinically defined acute disseminated encephalomyelitis and comparison with pathologically confirmed multiple sclerosis. Brain 133:333-48
113. Krupp LB, Banwell B, Tenembaum S. 2007. Consensus definitions proposed for pediatric multiple sclerosis and related disorders. Neurology 68:7-12
114. Leake JA, Billman GF, Nespeca MP, Duthie SE, Dory CE, et al. 2002. Pediatric acute hemorrhagic leukoencephalitis: report of a surviving patient and review. Clin. Infect. Dis. 34:699-703 (Pubitemid 34165335)
115. Hart MN, Earle KM. 1975. Haemorrhagic and perivenous encephalitis: a clinical-pathological review of 38 cases. J. Neurol. Neurosurg. Psychiatry 38:585-91
116. Ghosh N, DeLuca GC, Esiri MM. 2004. Evidence of axonal damage in human acute demyelinating diseases. J. Neurol. Sci. 222:29-34 (Pubitemid 38881503)
117. Lucchinetti CF, Parisi J, BruckW. 2005. The pathology of multiple sclerosis. Neurol. Clin. 23:77-105 (Pubitemid 40126916)
118. Gold R, Linington C, Lassmann H. 2006. Understanding pathogenesis and therapy of multiple sclerosis via animal models: 70 years of merits and culprits in experimental autoimmune encephalomyelitis research. Brain 129:1953-71 (Pubitemid 44289062)
119. Wingerchuk DM, Hogancamp WF, O'Brien PC, Weinshenker BG. 1999. The clinical course of neuromyelitis optica (Devic's syndrome). Neurology 53:1107-14 (Pubitemid 29442132)
120. Lucchinetti CF, Mandler RN, McGavern D, Bruck W, Gleich G, et al. 2002. A role for humoral mechanisms in the pathogenesis of Devic's neuromyelitis optica. Brain 125:1450-61 (Pubitemid 34755161)
121. Mandler RN, Davis LE, Jeffery DR, Kornfeld M. 1993. Devic's neuromyelitis optica: a clinicopathological study of 8 patients. Ann. Neurol. 34:162-68 (Pubitemid 23223043)
122. Wingerchuk DM, Lennon VA, Pittock SJ, Lucchinetti CF, Weinshenker BG. 2006. Revised diagnostic criteria for neuromyelitis optica. Neurology 66:1485-89 (Pubitemid 43958540)
123. Nielsen S, Nagelhus EA, Amiry-Moghaddam M, Bourque C, Agre P, Ottersen OP. 1997. Specialized membrane domains for water transport in glial cells: high-resolution immunogold cytochemistry of aquaporin-4 in rat brain. J. Neurosci. 17:171-80 (Pubitemid 27008860)
124. Pittock SJ, Weinshenker BG, Lucchinetti CF, Wingerchuk DM, Corboy JR, Lennon VA. 2006. Neuromyelitis optica brain lesions localized at sites of high aquaporin 4 expression. Arch. Neurol. 63:964-68 (Pubitemid 44036298)
125. Poppe AY, Lapierre Y, Melancon D, Lowden D, Wardell L, et al. 2005. Neuromyelitis optica with hypothalamic involvement. Mult. Scler. 11:617-21 (Pubitemid 41387709)
126. Viegas S, Weir A, Esiri M, Kuker W, Waters P, et al. 2009. Symptomatic, radiological and pathological involvement of the hypothalamus in neuromyelitis optica. J. Neurol. Neurosurg. Psychiatry 80:679-82
127. Nicchia GP, Nico B, Camassa LM, Mola MG, Loh N, et al. 2004. The role of aquaporin-4 in the blood-brain barrier development and integrity: studies in animal and cell culture models. Neuroscience 129:935-45 (Pubitemid 39556245)
128. Roemer SF, Parisi JE, Lennon VA, Benarroch EE, Lassmann H, et al. 2007. Pattern-specific loss of aquaporin-4 immunoreactivity distinguishes neuromyelitis optica from multiple sclerosis. Brain 130:1194-205 (Pubitemid 47355941)
129. Misu T, Fujihara K, Kakita A, Konno H, Nakamura M, et al. 2007. Loss of aquaporin 4 in lesions of neuromyelitis optica: distinction from multiple sclerosis. Brain 130:1224-34 (Pubitemid 47355951)
130. Popescu BF, Lennon VA, Parisi JE, Howe CL, Weigand SD, et al. 2011. Neuromyelitis optica unique area postrema lesions: nausea, vomiting and pathogenic implications. Neurology 76:1229-37
131. Hinson SR, Pittock SJ, Lucchinetti CF, Roemer SF, Fryer JP, et al. 2007. Pathogenic potential of IgG binding to water channel extracellular domain in neuromyelitis optica. Neurology 69:2221-31 (Pubitemid 350294677)
132. Benfenati V, Ferroni S. 2010. Water transport between CNS compartments: functional and molecular interactions between aquaporins and ion channels. Neuroscience 168:926-40
133. Pasantes-Morales H, Cruz-Rangel S. 2010. Brain volume regulation: osmolytes and aquaporin perspectives. Neuroscience 168:871-84
134. Hinson SR, Roemer SF, Lucchinetti CF, Fryer JP, Kryzer TJ, et al. 2008. Aquaporin-4-binding autoantibodies in patients with neuromyelitis optica impair glutamate transport by down-regulating EAAT2. J. Exp. Med. 205:2473-81
135. Matute C. 2007. Interaction between glutamate signalling and immune attack in damaging oligodendrocytes. Neuron Glia Biol. 3:281-85 (Pubitemid 351944151)
136. Badaut J, Lasbennes F, Magistretti PJ, Regli L. 2002. Aquaporins in brain: distribution, physiology, and pathophysiology. J. Cereb. Blood Flow Metab. 22:367-78 (Pubitemid 34273593)
137. Popescu BF, Parisi JE, Cabrera-Gomez JA, Newell K, Mandler RN, et al. 2010. Absence of cortical demyelination in neuromyelitis optica. Neurology 75:2103-9
138. Suzuki M, Obara K, Sasaki Y, Matoh K, Kitabatake A, et al. 2003. Comparison of perivascular astrocytic structure between white matter and gray matter of rats. Brain Res. 992:294-97 (Pubitemid 37415113)
139. Fenton RA, Moeller HB, Zelenina M, Snaebjornsson MT, Holen T, MacAulay N. 2010. Differential water permeability and regulation of three aquaporin 4 isoforms. Cell Mol. Life Sci. 67:829-40
140. Wingerchuk DM, Pittock SJ, Lucchinetti CF, Lennon VA, Weinshenker BG. 2007. A secondary progressive clinical course is uncommon in neuromyelitis optica. Neurology 68:603-5
141. Rocca MA, Agosta F, Mezzapesa DM, Martinelli V, Salvi F, et al. 2004. Magnetization transfer and diffusion tensor MRI show gray matter damage in neuromyelitis optica. Neurology 62:476-78 (Pubitemid 38200865)
142. Duvernoy HM, Risold PY. 2007. The circumventricular organs: an atlas of comparative anatomy and vascularization. Brain Res. Rev. 56:119-47 (Pubitemid 350110354)
143. Broadwell RD, Sofroniew MV. 1993. Serum proteins bypass the blood-brain fluid barriers for extracellular entry to the central nervous system. Exp. Neurol. 120:245-63 (Pubitemid 23165019)
144. Misu T, Fujihara K, Nakashima I, Sato S, Itoyama Y. 2005. Intractable hiccup and nausea with periaqueductal lesions in neuromyelitis optica. Neurology 65:1479-82 (Pubitemid 41552787)
145. Takahashi T, Miyazawa I, Misu T, Takano R, Nakashima I, et al. 2008. Intractable hiccup and nausea in neuromyelitis optica with anti-aquaporin-4 antibody: a herald of acute exacerbations. J. Neurol. Neurosurg. Psychiatry 79:1075-78
146. Apiwattanakul M, Popescu BF, Matiello M, Weinshenker BG, Lucchinetti CF, et al. 2010. Intractable vomiting as the initial presentation of neuromyelitis optica. Ann. Neurol. 68:757-61
147. Lee DH, Metz I, Berthele A, Stadelmann C, BruckW, et al. 2010. Supraspinal demyelinating lesions in neuromyelitis optica display a typical astrocyte pathology. Neuropathol. Appl. Neurobiol. 36:685-87
148. Takano R, Misu T, Takahashi T, Sato S, Fujihara K, Itoyama Y. 2010. Astrocytic damage is far more severe than demyelination in NMO: a clinical CSF biomarker study. Neurology 75:200-1
149. Papeix C, Vidal JS, de Seze J, Pierrot-Deseilligny C, Tourbah A, et al. 2007. Immunosuppressive therapy is more effective than interferon in neuromyelitis optica. Mult. Scler. 13:256-59 (Pubitemid 46592781)
150. Lassmann H. 2009. Experimental models of neuromyelitis optica. Rinsho Shinkeigaku 49:900-1